The company recently submitted its data to the federal regulatory authorities for an Emergency Use Authorization of its COVID-19 vaccine, NVX-CoV2373. As it's time to think about this potential vaccine being available in the US, clinicians offer some insights and perspective on it.
Triple COVID-19 vaccination or infection-plus-vaccination hybrid immunity induces high-quality antibodies, capable of neutralizing even the Omicron variant.
Economists from Johns Hopkins argue against government-mandated lockdowns and that they did not have the intended health care policy of protecting people during the pandemic.
The Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted 13-0 in favor of the vaccine for adults.
The VB variant likely originated in the late 1990s, and if left untreated, is more transmissible and deadly than prior HIV strains.
A sub-analysis of phase 2 data compared the immunogenicity of their VLA15 vaccine in adults after administration of 2 or 3 primary series doses with the latter demonstrating a stronger response.
COVID-19 patients who were vitamin D deficient before infection were 14 times more likely to have severe or fatal COVID-19 disease.
Findings could help in the development of “screening biomarkers and/or therapeutics,” authors say.
The first study to estimate rates of undiagnosed HIV in children across sub-Saharan Africa found significant gaps in HIV testing.
While Clostridioides difficile infection (CDI) risk appeared to drop, investigators said the overall risk of infection among patients was not changed in a statistically significant way.
Hospitals with lower c difficile antibiotic usage averaged shorter length-of-stay than hospitals that prescribed more antibiotics.
States that required ongoing medical doctor supervision of nurse practitioners and physician assistants had fewer HIV PrEP prescriptions.
Researchers could be one step closer to an HIV vaccine. This one uses mRNA technology.
Pfizer-BioNTech asked the FDA for Emergency Use Authorization to administer its COVID-19 vaccine to children 6 months-5 years of age, despite evidence that 2 vaccine doses may not be enough to elicit the desired immune response.
The company’s filing for its NVX-CoV2373 vaccine is based off data from 2 large clinical trials.
Veru inc. received FDA Fast Track designation for the phase 3 trial oral sabizabulin, a treatment for hospitalized COVID-19 patients at high risk of acute respiratory distress syndrome (ARDS) or death.
The FDA label expansion means adults living with HIV can now receive an injection of cabotegravir and rilpivirine (Cabenuva) once every 2 months instead of once monthly.
Health care workers in Taiwan who were previously infected with SARS-CoV-1 showed a more robust antibody response to the AstraZeneca COVID-19 vaccine, a new study found.
Backed by solid data, clinicians can work to overcome vaccine hesitancy due to fears about negative pregnancy outcomes.
Moderna recipients were less likely to experience COVID-19 breakthrough infections and hospitalizations than the Pfizer-BioNTech group.
The company’s Spikvax vaccine was approved based on its submission that included efficacy and safety data approximately 6 months after second dose.
The first study to use optical genome mapping to assess severely ill COVID-19 patients identified 7 key structural variants.
A booster vaccination increases protection against COVID-19 whether homologous or heterologous with the primary vaccine.
The Centers for Disease Control and Prevention (CDC) compared 2-dose mRNA vaccination to third dose booster and to unvaccinated, against both Omicron and Delta variants of SARS-CoV-2.
Before children were authorized to receive the Pfizer-BioNTech vaccine, living with 1-2 fully vaccinated parents significantly reduced children’s risk of COVID-19 infection during the Alpha and Delta periods.
In this first episode of Contagion Community, we interview vaccine research scientist Dr. Leonard Friedland about vaccination disparities in the US and around the world.
A new study sought to address how we approach treatments for these patients.
The study authors focused on eastern Europe and central Asia in their model, which included 4 scenarios for decriminalizing drug use and investing the savings into HIV transmission-reduction strategies.
The first doses of Moderna and IAVI’s mRNA HIV vaccine have been administered in the phase 1 IAVI G002 clinical trial.
The expectation of COVID-19 vaccination side effects may be leading some placebo recipients to report adverse events in vaccine trials.
